Nature Reviews Gastroenterology & Hepatology

Papers
(The TQCC of Nature Reviews Gastroenterology & Hepatology is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Cholangiocarcinoma 2020: the next horizon in mechanisms and management1084
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention829
Molecular and cellular mechanisms of liver fibrosis and its regression723
The International Scientific Association of Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of postbiotics676
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics623
Advances in immunotherapy for hepatocellular carcinoma575
Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders516
The four epidemiological stages in the global evolution of inflammatory bowel disease465
Pancreatic cancer stroma: an update on therapeutic targeting strategies433
Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma411
Liver regeneration: biological and pathological mechanisms and implications401
Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors358
Dietary fibre in gastrointestinal health and disease349
The complex link between NAFLD and type 2 diabetes mellitus — mechanisms and treatments332
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease317
Advancing the global public health agenda for NAFLD: a consensus statement312
The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on fermented foods307
Enteric nervous system: sensory transduction, neural circuits and gastrointestinal motility280
COVID-19 and liver disease: mechanistic and clinical perspectives256
Global burden of irritable bowel syndrome: trends, predictions and risk factors240
COVID-19: faecal–oral transmission?239
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms227
Potential intestinal infection and faecal–oral transmission of SARS-CoV-2211
Helicobacter pylori infection and antibiotic resistance — from biology to clinical implications190
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests176
Cell death in the gut epithelium and implications for chronic inflammation175
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications173
Gut microbiome, big data and machine learning to promote precision medicine for cancer170
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors167
The role of farnesoid X receptor in metabolic diseases, and gastrointestinal and liver cancer164
Therapeutic pipeline in nonalcoholic steatohepatitis162
COVID-19 and the other pandemic: populations made vulnerable by systemic inequity158
The gut microbiome as a modulator of healthy ageing157
Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis149
Cell death in pancreatic cancer: from pathogenesis to therapy148
From NAFLD to MAFLD: when pathophysiology succeeds148
AHR in the intestinal microenvironment: safeguarding barrier function147
Role of liver sinusoidal endothelial cells in liver diseases143
The multidisciplinary management of rectal cancer135
Intestinal epithelial glycosylation in homeostasis and gut microbiota interactions in IBD134
Cirrhosis-associated immune dysfunction133
Global burden and epidemiology of Barrett oesophagus and oesophageal cancer131
The intestinal barrier, an arbitrator turned provocateur in IBD130
Enteric glial biology, intercellular signalling and roles in gastrointestinal disease120
Brain–gut–microbiome interactions in obesity and food addiction119
Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology118
Gastrointestinal biofilms in health and disease116
Parkinson disease and the gut: new insights into pathogenesis and clinical relevance113
Modern therapeutic approaches for the treatment of malignant liver tumours112
Progress towards elimination goals for viral hepatitis110
Liver ischaemia–reperfusion injury: a new understanding of the role of innate immunity108
Polyploidy in liver development, homeostasis and disease106
Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment106
The role of goblet cells and mucus in intestinal homeostasis105
Evolving therapeutic landscape of advanced hepatocellular carcinoma105
Dietary carbohydrates and fats in nonalcoholic fatty liver disease103
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma102
The evolution and clinical impact of hepatitis B virus genome diversity99
COVID-19 and acute pancreatitis: examining the causality99
Current and future colorectal cancer screening strategies98
Disorders of the enteric nervous system — a holistic view95
The pancreatic cancer genome revisited93
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure92
NAFLD — sounding the alarm on a silent epidemic89
Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors87
Faecal microbiota transplantation for Clostridioides difficile: mechanisms and pharmacology86
Nonalcoholic fatty liver disease: another leap forward86
Microbiome risk profiles as biomarkers for inflammatory and metabolic disorders85
Management of IBD during the COVID-19 outbreak: resetting clinical priorities85
Leveraging diet to engineer the gut microbiome84
Global epidemiology of cirrhosis — aetiology, trends and predictions80
Neutrophils as potential therapeutic targets in hepatocellular carcinoma77
Harnessing metabolic dependencies in pancreatic cancers77
The role of oral bacteria in inflammatory bowel disease77
Recipient factors in faecal microbiota transplantation: one stool does not fit all72
A risk-stratified approach to colorectal cancer prevention and diagnosis71
Revisiting fibrosis in inflammatory bowel disease: the gut thickens70
The metabolic nature of inflammatory bowel diseases69
Defining comprehensive models of care for NAFLD67
Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight66
Gut microbiota as a transducer of dietary cues to regulate host circadian rhythms and metabolism66
New insights into IL-6 family cytokines in metabolism, hepatology and gastroenterology65
Early detection of pancreatic cancer using DNA-based molecular approaches65
Understanding the physiology of human defaecation and disorders of continence and evacuation65
Viral hepatitis and pregnancy63
Foundations of gastrointestinal-based drug delivery and future developments63
Maladaptive regeneration — the reawakening of developmental pathways in NASH and fibrosis62
Postbiotics — when simplification fails to clarify61
Location is important: differentiation between ileal and colonic Crohn’s disease61
Circadian clocks in the digestive system61
Intra-pancreatic fat deposition: bringing hidden fat to the fore60
Hippo signalling in the liver: role in development, regeneration and disease60
Understanding, predicting and achieving liver transplant tolerance: from bench to bedside60
Breakthroughs in hepatitis C research: from discovery to cure59
Current and emerging therapies for coeliac disease58
Gut microbiota in COVID-19: key microbial changes, potential mechanisms and clinical applications57
Bench to bedside — new insights into the pathogenesis of necrotizing enterocolitis56
The promise of the gut microbiome as part of individualized treatment strategies56
Current developments in gastric cancer: from molecular profiling to treatment strategy55
Optimizing biologic therapy in IBD: how essential is therapeutic drug monitoring?54
Human biomimetic liver microphysiology systems in drug development and precision medicine53
Mechanisms of mucosal healing: treating inflammatory bowel disease without immunosuppression?53
International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease52
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment52
Paracellular permeability and tight junction regulation in gut health and disease52
Sex matters: impact on pathogenesis, presentation and treatment of inflammatory bowel disease51
Gastrointestinal post-acute COVID-19 syndrome51
Development of AI-based pathology biomarkers in gastrointestinal and liver cancer50
COVID-19 and liver transplantation50
Gut feelings: mechanosensing in the gastrointestinal tract48
Multiomics to elucidate inflammatory bowel disease risk factors and pathways48
Management of alcohol use disorder in patients with cirrhosis in the setting of liver transplantation48
Regulation and functional roles of chemokines in liver diseases46
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook46
The war against pancreatic cancer in 2020 — advances on all fronts44
Bacteriophages and their potential for treatment of gastrointestinal diseases44
Global burden of hepatitis B virus: current status, missed opportunities and a call for action44
COVID-19 and the liver-related deaths to come43
The immune microenvironment in gastric adenocarcinoma43
Evidence-based and mechanistic insights into exclusion diets for IBS41
Next-generation robotics in gastrointestinal surgery41
Single-cell RNA sequencing in pancreatic cancer40
Dietary management of adults with IBD — the emerging role of dietary therapy39
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease39
When the minority tax is doubled: being Black and female in academic medicine37
Hepatic inflammatory responses in liver fibrosis35
IgG4-related diseases of the digestive tract35
Head-to-head trials in inflammatory bowel disease: past, present and future35
SARS-CoV-2 vaccination in IBD: more pros than cons35
Extending treatment eligibility for chronic hepatitis B virus infection34
Optimizing immunotherapy for colorectal cancer34
The global burden of coeliac disease: opportunities and challenges33
Society for the Study of Celiac Disease position statement on gaps and opportunities in coeliac disease33
Updated epidemiology of gastrointestinal cancers in East Asia32
Therapeutic landscape and future direction of metastatic colorectal cancer30
Machine perfusion of the liver: applications in transplantation and beyond29
COVID-19 and endoscopy: implications for healthcare and digestive cancer screening29
How academia should respond to racism28
Hepatitis C virus elimination: laying the foundation for achieving 2030 targets28
Gut immune cell trafficking: inter-organ communication and immune-mediated inflammation27
Transcriptional programmes underlying cellular identity and microbial responsiveness in the intestinal epithelium27
Exploring liver cancer biology through functional genetic screens27
Immunology and immunotherapy of cholangiocarcinoma26
Nomenclature of HBV core protein-targeting antivirals25
Gut–liver axis: barriers and functional circuits23
What are the clinical settings and outcomes of lean NAFLD?23
COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology23
Antibiotics in the pathogenesis of diabetes and inflammatory diseases of the gastrointestinal tract23
Macrophages in intestinal homeostasis and inflammatory bowel disease23
Lifestyle interventions in nonalcoholic fatty liver disease22
The scientific basis of combination therapy for chronic hepatitis B functional cure22
The microbiota and the gut–liver axis in primary sclerosing cholangitis22
Capturing the environment of the Clostridioides difficile infection cycle22
Methanogenic archaea in the human gastrointestinal tract21
A framework for fibrolamellar carcinoma research and clinical trials21
Artificial intelligence and automation in endoscopy and surgery21
Reply to: Postbiotics — when simplification fails to clarify20
0.024509906768799